Researchers are targeting tau protein with drugs designed to either slow its spread through the brain, prevent it from clumping into toxic tangles, or clear it away entirely—and the first of these drugs are now in human testing. Tau is a protein that normally helps stabilize a brain cell’s internal structure, but in diseases like Alzheimer’s and frontotemporal dementia, it misfolds, accumulates, and spreads from neuron to neuron like a corrupted message, eventually killing the cells it infects. Unlike amyloid-beta, which has dominated Alzheimer’s research for decades, tau was largely overlooked until brain imaging technologies made it visible and autopsy studies proved it was the stronger predictor of cognitive decline.
Now, with tau finally in the spotlight, pharmaceutical companies and academic researchers are testing more than a dozen different approaches to interrupt this cascade. What makes these trials significant is that they represent the first time we’re not just slowing cognitive decline but attempting to directly interfere with the tau pathology itself—not the downstream damage, but the protein’s ability to spread and accumulate. Some trials use monoclonal antibodies that grab onto tau and mark it for destruction, others use small molecules that prevent tau from misfolding, and still others aim to enhance the brain’s natural cleanup mechanisms.
Table of Contents
- What Exactly Are Anti-Tau Clinical Trials Testing?
- How Does Tau Spread Through the Brain, and Why Is That a Problem?
- What Types of Anti-Tau Treatments Are Currently in Testing?
- Who Can Join Anti-Tau Clinical Trials, and What Should People Know Before Enrolling?
- Why Have Some Anti-Tau Trials Slowed or Been Discontinued?
- When Might Anti-Tau Drugs Become Available Outside of Trials?
- How Do Anti-Tau Trials Differ From the Anti-Amyloid Trials We’ve Heard About?
What Exactly Are Anti-Tau Clinical Trials Testing?
Anti-tau clinical trials are research studies that test drugs or biologics designed to disrupt the tau cascade at different points. The most common approach uses monoclonal antibodies—synthetic proteins that act like targeted hunters, binding to specific forms of tau and either preventing it from spreading cell-to-cell or flagging it for the immune system to clear. Eli Lilly’s lecanemab (already approved for early Alzheimer’s disease) actually targets amyloid, but Eli Lilly also has tilavonemab and other tau-directed antibodies in trials. Other companies like AC Immune and Roche are testing different antibodies that target tau at various stages of its misfolding.
Another class of anti-tau drugs uses small molecules—tiny pills rather than infusions—that stabilize tau and prevent it from forming tangles in the first place. A major difference between anti-tau and anti-amyloid trials is that tau appears much later in disease development and spreads more predictably through specific brain regions. This means anti-tau treatments might help people further along in their disease progression, whereas amyloid-targeting drugs like lecanemab and donanemab work best in the preclinical or very early symptomatic stages. In trials like the PRIME study and the ARCHITECT trial, researchers are enrolling people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, measuring not just cognition but also tau levels in cerebrospinal fluid and tau accumulation on PET imaging.
How Does Tau Spread Through the Brain, and Why Is That a Problem?
Normal tau protein works like a railroad track, holding the internal skeleton of neurons together so materials can move within the cell. When tau misfolds—often triggered by inflammation, oxidative stress, or amyloid accumulation—it loses this function and instead sticks to other tau molecules, forming tangles. These tangles don’t just gum up a single cell; they appear to spread from neuron to neuron through synaptic connections, like a slow-moving domino cascade that can take decades to cross the brain. Importantly, tau spread follows the anatomy of brain networks, so a tangle that starts in the entorhinal cortex (a memory hub) will predictably invade the hippocampus, then the temporal lobe, and eventually the cortex where our conscious thoughts happen.
The challenge with tau is that by the time someone notices memory problems or confusion, tau has usually been accumulating for 10–20 years already. Studies of cognitively normal older adults using PET imaging show that half of people over 80 have significant tau pathology but no symptoms—the brain can compensate for some damage. Once tau crosses a threshold or spreads to the temporal and cortical regions, that compensation fails, and dementia becomes visible. This is why researchers are now trying to block tau spread earlier in the disease, either in asymptomatic people with amyloid and tau both present (as detected by blood tests), or in early symptomatic stages. A major limitation is that tau may not be the only driver of neurodegeneration; inflammation, other proteins like TDP-43, and factors like cerebrovascular disease also contribute, meaning an anti-tau drug alone might slow but not stop cognitive decline in many people.
What Types of Anti-Tau Treatments Are Currently in Testing?
The landscape of anti-tau drugs includes several distinct mechanisms. Monoclonal antibodies like gosuranemab (developed by Eli Lilly but put on hold after a Phase 2 trial showed amyloid-related imaging abnormalities, or ARIA, a brain microhemorrhage risk) and semorinemab (tested in a chronic traumatic encephalopathy population) target extracellular tau—tau that has left the cell and is spreading through the brain. Other antibodies like ulotaront (by Eli Lilly) and UCB0599 (by UCB) target intracellular tau, the toxic clumps forming inside neurons. Meanwhile, small-molecule approaches like anle138b (being tested by Prion Biotech in collaboration with the German Center for Neurodegenerative Diseases) and others aim to prevent tau from misfold and polymerizing in the first place.
Immunotherapy is also being explored: some researchers are testing tau-based vaccines that would train the immune system to recognize and attack misfolded tau, similar in concept to cancer vaccines. The benefit of these many approaches is that if one mechanism fails or doesn’t work for everyone, there are backups. The downside is that most of these trials are still early-phase (Phase 1b or Phase 2), and only a handful have shown clear slowing of cognitive decline. For example, the Phase 2 study of semorinemab in CTE showed a trend toward slowing cognitive decline but did not reach statistical significance, highlighting how difficult it is to prove benefit even in well-designed trials. Brain penetration is also a hurdle—the blood-brain barrier blocks large antibodies from reaching deep brain structures effectively, which is one reason small molecules are generating interest despite being harder to engineer for specificity.
Who Can Join Anti-Tau Clinical Trials, and What Should People Know Before Enrolling?
Anti-tau trials are enrolling several populations depending on the drug and stage of development. Early trials (Phase 1, Phase 1b) enroll small numbers of healthy volunteers or people with very early cognitive changes to establish safety and dosing. Later trials (Phase 2, Phase 3) focus on people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, confirmed either by positive amyloid and tau PET scans or increasingly by blood biomarkers (phosphorylated tau, p-tau181 or p-tau217). Some trials are also enrolling based on cognitively normal status with amyloid-PET positivity and elevated tau biomarkers—essentially, people who show the pathology but not yet the symptoms. Eligibility typically requires cognitive testing (MMSE or Montreal Cognitive Assessment scores in a certain range), sometimes brain imaging, blood work, and willingness to undergo frequent clinic visits or PET scans.
A critical thing to understand is that these are research trials, not guaranteed treatments. Participants might receive placebo or active drug, and even those on active drug don’t know if it will help them specifically. Side effects of anti-tau antibodies have included ARIA—microhemorrhages or microinfarcts in the brain that don’t always cause symptoms but can show up on MRI. Gosuranemab was deprioritized partly because of higher ARIA rates in tau-targeting trials compared to amyloid-targeting ones, suggesting that clearing tau might activate microglial inflammation differently. People considering enrollment should also ask about whether the trial has long-term follow-up data, how results will be communicated, and what support is available if they experience imaging-confirmed brain changes.
Why Have Some Anti-Tau Trials Slowed or Been Discontinued?
Several anti-tau programs have hit obstacles that illustrate the real complexity of tau-targeted therapy. Eli Lilly discontinued gosuranemab after a Phase 2 trial showed amyloid-related imaging abnormalities in treated participants, raising questions about whether clearing tau triggers inflammation that damages blood vessels. Other programs faced slow enrollment, partly because identifying people with tau pathology requires either PET scanning (expensive, not widely available) or relatively new blood biomarkers that many clinicians still don’t order routinely. This is different from the amyloid-targeting space, where drugs like lecanemab and donanemab had large pre-screened populations and clearer biomarker selection criteria.
Another limitation is that tau trials have often enrolled people already on amyloid-targeting drugs or who have mixed amyloid and tau pathology, making it harder to isolate tau’s specific effect. A trial that shows 30% slowing of decline might still feel modest if participants lose multiple months of independence per year, and regulatory pathways for “slowing” (rather than halting or reversing) neurodegenerative disease are still being defined. Additionally, tau might not be equally important across all dementia types or individuals; some people with high tau burden remain cognitively intact due to brain reserve or other protective factors, while others decline despite lower tau. This person-to-person variability means that trials must be large and well-powered, driving up costs and timelines.
When Might Anti-Tau Drugs Become Available Outside of Trials?
It’s difficult to predict, but based on the current pipeline and FDA precedent, anti-tau monoclonal antibodies are likely 3–7 years away from potential approval if pivotal Phase 3 trials show meaningful efficacy. Eli Lilly, Roche, and AC Immune all have programs in Phase 2, but none have yet reported phase 3 primary-endpoint readouts. The approval of lecanemab (an anti-amyloid monoclonal antibody) in 2023 showed that the FDA will approve disease-modifying Alzheimer’s drugs that produce modest slowing—lecanemab slowed cognitive decline by about 27% over 18 months in early symptomatic disease.
If an anti-tau drug shows similar or better efficacy, it could potentially follow a faster pathway. However, the bar may be higher because of the ARIA safety concerns seen in some tau trials. Small-molecule anti-tau drugs, if they prove effective, might eventually offer easier administration (daily pill instead of monthly or quarterly infusion), which could improve real-world adherence. But these are earlier in development and face the additional hurdle of showing that they cross the blood-brain barrier in sufficient concentration and don’t have off-target effects in other organs.
How Do Anti-Tau Trials Differ From the Anti-Amyloid Trials We’ve Heard About?
The key difference is timing and disease stage. Anti-amyloid drugs like lecanemab and donanemab work best when given to people in the preclinical or very early symptomatic phase—essentially, while amyloid accumulation is still happening and neurodegeneration is minimal. Anti-tau drugs, by contrast, are being tested in people further along in cognitive decline (mild cognitive impairment or mild dementia stages) because tau spread accelerates with amyloid burden and only becomes the dominant driver later in disease. This also means anti-tau drugs might benefit a different population: people who have already lost the window for amyloid-targeting therapy, or those who took amyloid drugs but still declined (suggesting tau is the driving factor). Another difference is the imaging signal. Amyloid can be present for decades with minimal tau, but tau, once it starts spreading, accelerates toward cognitive symptoms much faster.
This means anti-tau trials can potentially enroll more symptomatic patients and measure cognitive decline over shorter timelines—an advantage for faster trial completion. However, tau is also more heterogeneous; it accumulates in different regional patterns depending on disease type (Alzheimer’s vs. primary age-related tauopathy vs. frontotemporal dementia), so a single anti-tau drug may not work equally well across all these conditions. Amyloid, by contrast, follows a more uniform pattern. Some researchers are now combining anti-amyloid and anti-tau approaches in early preclinical trials, hypothesizing that targeting both pathologies simultaneously might produce better outcomes than either alone.
- —



